# LSBiotm Human SERPINE1 / PAI-1 ELISA Kit

Catalog No. LS-F10421

## **User Manual**

Please Read the Manual Carefully Before Starting your Experiment



For research use only. Not approved for use in humans or for clinical diagnosis.



### **Human PAI-1 Total Antigen ELISA Kit**

Catalog # LS-F10421 Strip well format.

Rev: December, 2014

Reagents for up to 96 tests.

www.lsbio.com

#### **INTENDED USE**

This human plasminogen activator inhibitor type 1 (PAI-1) total antigen assay is intended for the quantitative determination of total PAI-1 in human plasma in citrate, EDTA or heparin, serum, cell culture media, tissue lysates and other biological fluids. For research use only.

#### **BACKGROUND**

PAI-1 is involved in the regulation of the blood fibrinolytic system. Increased plasma levels of PAI-1 are implicated in the impairment of fibrinolytic function and may be associated with thrombotic diseases [1,2]. Levels of PAI-1 increase with age [3] and are elevated in conditions such as normal pregnancy [4], sepsis [5] and obesity [6].

#### **ASSAY PRINCIPLE**

Human PAI-1 will bind to the monoclonal capture antibody coated on the microtiter plate. Free, latent, and complexed PAI-1 will bind to the plate. After appropriate washing steps, polyclonal anti-human PAI-1 primary antibody binds to the captured protein. Excess primary antibody is washed away and bound antibody is reacted with peroxidase conjugated secondary antibody. Following an additional washing step, TMB substrate is used for color development at 450nm. A standard calibration curve is prepared along with the samples to measured using dilutions of human PAI-1. Color development is proportional to the concentration of PAI-1 in the samples.

#### **REAGENTS PROVIDED**

- •96-well antibody coated microtiter strip plate (removable wells 8x12) containing anti-human PAI-1 capture antibody, blocked and dried.
- •10X Wash buffer: 1 bottle of 50ml
- Human PAI-1 standard: 1 vial lyophilized standard Antihuman PAI-1 primary antibody: 1 vial lyophilized polyclonal antibody
- Horseradish peroxidase-conjugated anti-rabbit secondary antibody: 1 vial concentrated HRP labeled antibody
- •TMB substrate solution: 1 bottle of 10ml solution

#### STORAGE AND STABILITY

Store all kit components at 4°C upon arrival. Return any unused microplate strips to the plate pouch with desiccant. Reconstituted standards and primary may be stored at -80°C for later use. Do not freeze-thaw the standard and primary antibody more than once. Store all other unused kit components at 4°C. This kit should not be used beyond the expiration date.

#### OTHER REAGENTS AND SUPPLIES REQUIRED

- Microtiter plate shaker capable of 300 rpm uniform horizontally circular movement
- Manifold dispenser/aspirator or automated microplate washer
- •Microplate reader capable of measuring absorbance at 450 nm
- Pipettes and Pipette tips
- Deionized or distilled water
- Polypropylene tubes for dilution of standard
- Paper towels or laboratory wipes
- •1N H<sub>2</sub>SO<sub>4</sub> or 1N HCl
- Bovine Serum Albumin Fraction V (BSA)
- Tris(hydroxymethyl)aminomethane (Tris)
- Sodium Chloride (NaCl)

#### **PRECAUTIONS**

- •FOR LABORATORY RESEARCH USE ONLY. NOT FOR be DIAGNOSTIC USE.
- Do not mix any reagents or components of this kit with any reagents or components of any other kit. This kit is designed to work properly as provided.
- Always pour peroxidase substrate out of the bottle into a clean test tube. Do not pipette out of the bottle as contamination could result.
- Keep plate covered except when adding reagents, washing, or reading.
- DO NOT pipette reagents by mouth and avoid contact of reagents and specimens with skin.
- •DO NOT smoke, drink, or eat in areas where specimens or reagents are being handled.

#### PREPARATION OF REAGENTS

•TBS buffer: 0.1M Tris, 0.15M NaCl, pH 7.4 •Blocking buffer (BB): 3% BSA (w/v) in TBS

•1X Wash buffer: Dilute 50ml of 10X wash buffer concentrate with 450ml of deionized water.

#### **SAMPLE COLLECTION**

Collect plasma using citrate, EDTA or heparin as an anticoagulant. Immediately after collection of blood, samples must be centrifuged at 3000Xg for 15 minutes. It is important to ensure a platelet free preparation as platelets can release PAI-1. Assay immediately or aliquot and store at  $\leq$  -20°C. Avoid repeated freeze-thaw cycles.

#### **ASSAY PROCEDURE**

Perform assay at room temperature. Vigorously shake plate (300rpm) at each step of the assay.

#### **Preparation of Standard**

Reconstitute standard by adding 1ml of blocking buffer directly to the vial and agitate gently to completely dissolve contents. This will result in a 1,000ng/ml standard solution.

Dilution table for preparation of human PAI-1 standard:

PAI-1 concentration (ng/ml)	Dilutions				
100	900µl (BB) + 100µl (from vial)				
50	500µl (BB) + 500µl (100ng/ml)				
25	500µl (BB) + 500µl (50ng/ml)				
10	600µl (BB) + 400µl (25ng/ml)				
5	500µl (BB) + 500µl (10ng/ml)				
2	600µl (BB) + 400µl (5ng/ml)				
1	500µl (BB) + 500µl (2ng/ml)				
0.5	500µl (BB) + 500µl (1ng/ml)				
0.25	500µl (BB) + 500µl (0.5ng/ml)				
0	500µl (BB) Zero point to determine background				

NOTE: DILUTIONS FOR THE STANDARD CURVE AND ZERO STANDARD MUST BE MADE AND APPLIED TO THE PLATE IMMEDIATELY.

#### **Standard and Unknown Addition**

Remove microtiter plate from bag and add 100 $\mu$ l PAI-1 standards (in duplicate) and unknowns to wells. Carefully record position of standards and unknowns. Shake plate at 300rpm for 30 minutes. Wash wells three times with 300 $\mu$ l wash buffer. Remove excess wash by gently tapping plate on paper towel or kimwipe.

NOTE: The assay measures PAI-1 antigen in the 0.25-100 ng/ml range. If the unknown is thought to have high PAI-1 levels, dilutions may be made in plasma devoid of PAI-1 or in blocking buffer. A 1:10 to 1:100 dilution for normal plasma is suggested for best results.

#### **Primary Antibody Addition**

Reconstitute primary antibody by adding 10ml of blocking buffer directly to the vial and agitate gently to completely dissolve contents. Add 100µl to all wells. Shake plate at 300rpm for 30 minutes. Wash wells three times with 300µl wash buffer. Remove excess wash by gently tapping plate on paper towel or kimwipe.

#### **Secondary Antibody Addition**

Briefly centrifuge vial before opening. Dilute  $1\mu$ l of conjugated secondary antibody in 10ml of blocking buffer and add  $100\mu$ l to all wells. Shake plate at 300rpm for 30 minutes. Wash wells three times with  $300\mu$ l wash buffer. Remove excess wash by gently tapping plate on paper towel or kimwipe.

#### **Substrate Incubation**

Add  $100\mu$ l TMB substrate to all wells and shake plate for 2-10 minutes. Substrate will change from colorless to different strengths of blue. Quench reaction by adding  $50\mu$ l of 1N H<sub>2</sub>SO<sub>4</sub> or HCl stop solution to all wells when samples are visually in the same range as the standards. Add stop solution to wells in the same order as substrate upon which color will change from blue to yellow. Mix thoroughly by gently shaking the plate.


#### Measurement

Set the absorbance at 450nm in a microtiter plate spectrophotometer. Measure the absorbance in all wells at 450nm. Subtract zero point from all standards and unknowns to determine corrected absorbance (A<sub>450</sub>).

#### **Calculation of Results**

Plot A<sub>450</sub> against the amount of PAI-1 in the standards. Fit a straight line through the linear points of the standard curve using a linear fit procedure if unknowns appear on the linear portion of the standard curve. Alternatively, create a standard curve by analyzing the data using a software program capable of generating a four parameter logistic (4PL) curve fit. The amount of PAI-1 in the unknowns can be determined from this curve. If samples have been diluted, the calculated concentration must be multiplied by the dilution factor.

A typical standard curve (EXAMPLE ONLY):



#### **EXPECTED VALUES**

The concentration level of PAI-1 antigen in pooled normal human plasma ranged from 7.4-28 ng/ml [8]. A

Total Human PAI-1 (ng/mL)

study of platelet abnormalities found that the PAI-1 concentration of normal platelet-free plasma was 21.0  $\pm$  7.2 ng/ml (mean  $\pm$  SD), platelet-rich plasma was 282.6  $\pm$  68.0 ng/ml and serum was 270.3  $\pm$  71.9 ng/ml [9]. Patients with platelet abnormalities had similar PAI-1 values in PFP, PRP and serum.

#### PERFORMANCE CHARACTERISTICS

**Sensitivity:** The minimum detectable dose (MDD) was determined by adding two standard deviations to the mean optical density value of twenty zero standard replicates (range OD<sub>450</sub>: 0.064-0.074) and calculating the corresponding concentration. The MDD was 0.037ng/ml.

**Intra-assay Precision:** Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

Sample	1	2	3	
n	20	20	20	
Mean (ng/ml)	0.46	3.31	36.4	
Standard Deviation	0.037	0.103	2.39	
CV (%)	7.89	3.13	6.58	

**Inter-assay Precision:** Three samples of known concentration were tested in ten independent assays to assess inter-assay precision.

Sample	1	2	3	
n	10	10	10	
Mean (ng/ml)	0.34	3.00	36.3	
Standard Deviation	0.027	0.115	2.76	
CV (%)	8.10	3.83	7.60	

**Recovery:** The recovery of antigen spiked to levels throughout the range of the assay in blocking buffer was evaluated.

Sample	1	2	3	4	
n	4	4	4	4	
Mean (ng/ml)	0.30	0.53	5.59	56.5	
Average % Recovery	100	97	93	103	
Range	93- 109%	92- 103%	91- 96%	97- 108%	

**Linearity:** To assess the linearity of the assay, pooled citrated human plasma samples containing high concentrations of antigen were serially diluted to produce samples with values within the dynamic range of the assay.

Sample	1:2	1:4	1:8	1:16	
n	4	4	4	4	
Average % of Expected	102	98	104	102	
Range	98- 108%	97- 100%	100- 109%	98- 104%	

**Specificity:** This assay recognizes natural and recombinant human PAI-1. Significant cross reaction is observed with pooled normal plasma from rabbit. Pooled normal plasma from cyno monkey, porcine, mouse, rat, horse and sheep were assayed for cross-

reactivity. No significant cross-reactivity was observed.

**Sample Values:** Samples were evaluated for the presence of the antigen at varying dilutions.

Sample Type	Dilution	Mean (ng/mL)		
Citrata Diasma	1:10	162		
Citrate Plasma	1:100	211		
Codium EDTA Dlasma	1:10	83		
Sodium EDTA Plasma	1:100	89		
K3 EDTA Plasma	1:10	37		
KS EDTA PIdSIIId	1:100	38		
Honorin Dlacma	1:10	150		
Heparin Plasma	1:100	188		
Corum	1:10	81		
Serum	1:100	93		

#### **DISCLAIMER**

This information is believed to be correct but does not claim to be all-inclusive and shall be used only as a guide. The supplier of this kit shall not be held liable for any damage resulting from handling of or contact with the above product.

#### **REFERENCES**

- 1. Yamamoto K, *et al.*: Proc. Natl. Acad. Sci. USA. 2002, 99:890-5.
- 2. Chavakis T, et al.: J. Biol. Chem. 2002, 277:32677-82.
- 3. Kruithof EK, et al.: Blood 1987, 70:1645-53.
- 4. Wiman B, et al.: Thromb. Haemostas. 1984, 52:124-6. 5. Colucci M, et al.: J. Clin. Invest. 1985, 75:818-24.
- 6. Alessi MC, *et al.*: Arterioscler. Thromb. Vasc. Biol. 2003, 23:1262-68.
- 7.Declerck PJ, et al.: Blood 1988, 71(1): 220-5.
- 8. Declerck PJ, *et al.*: Thromb. Haemostas. 1993, 70:858-63.
- 9. Booth, NA et al.: Br J Haematol. 1988, 70: 327-333.

#### **Example of ELISA Plate Layout**

96 Well Plate: 20 Standard wells, 76 Sample wells

	1	2	3	4	5	6	7	8	9	10	11	12
Α	0	0.25 ng/ml	0.5 ng/ml	1 ng/ml	2 ng/ml	5 ng/ml	10 ng/ml	25 ng/ml	50 ng/ml	100 ng/ml		
В	0	0.25 ng/ml	0.5 ng/ml	1 ng/ml	2 ng/ml	5 ng/ml	10 ng/ml	25 ng/ml	50 ng/ml	100 ng/ml		
С		HE/IIII	HIZ/IIII	HISTHII	HZ/IIII	IIg/IIII	HIZ/IIII	IIg/IIII	HZ/IIII	Hg/IIII		
D												
E F												
G												
Н												

**Important Note:** During shipment, small volumes of product will occasionally become entrapped in the seal of the product vial. We recommend briefly centrifuging the vial to dislodge any liquid in the container's cap prior to opening.

**Warning:** This reagent may contain sodium azide and sulfuric acid. The chemical, physical, and toxicological properties of these materials have not been thoroughly investigated. Standard Laboratory Practices should be followed. Avoid skin and eye contact, inhalation, and ingestion. Sodium azide forms hydrazoic acid under acidic conditions and may react with lead or copper plumbing to form highly explosive metal azides. On disposal, flush with large volumes of water to prevent accumulation.

**Returns, Refunds, Cancelations:** Any problems with LifeSpan products must be reported to LifeSpan within 10 days of product receipt. The customer must obtain written authorization from LifeSpan before returning items. To request that goods be returned, please contact LifeSpan Technical Support. If an error by LifeSpan BioSciences results in shipment of an incorrect order, LifeSpan will, at its option, either ship a replacement order at no charge, or credit the customer's account for the original product shipped in error. Returns and cancelations may be subject to a 30% restocking fee.

Conditions & Warranty: All LifeSpan products are intended for Research Use Only and are not for use in human therapeutic or diagnostic applications. The information supplied with each product is believed to be accurate, but no warranty or guarantee is offered for the products, because the ultimate conditions of use are beyond LifeSpan's control. The information supplied with each product is not to be construed as a recommendation to use this product in violation of any patent, and LifeSpan will not be held responsible for any infringement or other violation that may occur with the use of its products. Under no event will LifeSpan be responsible for any loss of profit or indirect consequential damage, including, but not limited to, personal injuries resulting from use of these products. LifeSpan's liability to any user of Products for damages that do not result from any fault of the user, will be limited to replacement of the Product(s) only, and in no event shall LifeSpan's liability exceed the actual price received by LifeSpan for the Product(s) at issue. LifeSpan shall not be liable for any indirect, special, incidental or consequential damages. LIFESPAN FURTHER DISCLAIMS ANY AND ALL EXPRESS AND IMPLIED OR STATUTORY WARRANTIES WITH RESPECT TO THE PRODUCTS, INCLUDING BUT NOT LIMITED TO ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE. LifeSpan disclaims any and all responsibility for any injury or damage which may be caused by the fault of the user.

For research use only. Not approved for use in humans or for clinical diagnosis.



2401 Fourth Avenue Suite 900 Seattle, WA 98121 Tel: 206.374.1102

Fax: 206.577.4565

Technical.Support@LSBio.com